추천 제품
Quality Level
분석
≥98% (HPLC)
양식
powder
색상
white to tan
solubility
DMSO: ≥15 mg/mL
주관자
Sanofi Aventis
저장 온도
2-8°C
SMILES string
Cc1ccccc1C(=O)Nc2ccc(c(C)c2)C(=O)N3CCCC(O)c4cc(Cl)ccc34
InChI
1S/C26H25ClN2O3/c1-16-6-3-4-7-20(16)25(31)28-19-10-11-21(17(2)14-19)26(32)29-13-5-8-24(30)22-15-18(27)9-12-23(22)29/h3-4,6-7,9-12,14-15,24,30H,5,8,13H2,1-2H3,(H,28,31)
InChI key
GYHCTFXIZSNGJT-UHFFFAOYSA-N
유전자 정보
human ... AVPR2(554)
애플리케이션
Tolvaptan has been used as a V2-selective antagonist for studying its effect on hypertension in mice.
생화학적/생리학적 작용
Tolvaptan (OPC 41061) is a potent, orally active non-peptide vasopressin V2 selective antagonist. IC50 = 3 nM at the rat V2 receptor; 29 times more selective for the V2 than for V1a. Tolvaptan has also been shown to inhibit the development of polycystic kidney disease in several animal models.
특징 및 장점
This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
제조 메모
Tolvaptan is soluble in DMSO at a concentration that is greater than or equal to 15 mg/ml.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
가장 최신 버전 중 하나를 선택하세요:
시험 성적서(COA)
이미 열람한 고객
American journal of physiology. Regulatory, integrative and comparative physiology, 304(10), R818-R828 (2013-03-29)
An indispensable role for the brain renin-angiotensin system (RAS) has been documented in most experimental animal models of hypertension. To identify the specific efferent pathway activated by the brain RAS that mediates hypertension, we examined the hypothesis that elevated arginine
Circulation journal : official journal of the Japanese Circulation Society, 77(2), 397-404 (2012-11-08)
A newly-developed vasopressin type 2 receptor antagonist, tolvaptan (TLV), has a unique feature of diuresis, but the response to this drug can be unpredictable. Data were collected from hospitalized patients with decompensated congestive heart failure who were administered TLV at
Urine osmolality-guided tolvaptan therapy in decompensated heart failure.
Circulation journal : official journal of the Japanese Circulation Society, 77(2), 313-314 (2012-12-28)
Journal of the American College of Cardiology, 61(5), 571-579 (2012-12-19)
The study investigated whether the number of participants enrolled per site in an acute heart failure trial is associated with participant characteristics and outcomes. Whether and how site enrollment volume affects clinical trials is not known. A total of 4,133
Pharmacology research & perspectives, 8(5), e00659-e00659 (2020-10-01)
Cyclophosphamide (CP) is a chemotherapeutic agent which is extensively used in the treatment of multiple neoplastic and nonneoplastic diseases like breast cancer, lymphomas, systemic lupus erythematosus, and multiple sclerosis. Dose-limiting side effects, mainly nephrotoxicity is a major problem hindering its
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.